EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, OCTOBER 3, 2019
Media advisory: The full study and podcast are linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2019.3323?guestAccessKey=583f4614-cd6e-4be8-96a9-8db42b4763dd&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=100319
What The Study Did: Researchers estimated the cost-effectiveness and health effects of multigene testing for all patients with breast cancer compared with selective testing based on family history or clinical criteria using data for nearly 12,000 women with breast cancer from the U.S., U.K. and Australia.
Authors: Ranjit Manchanda, M.D., Ph.D., of the Queen Mary University of London, is the corresponding author.
Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.